Movement Alert｜INNOVENT BIO Rises 4.43% in Regular Trading, Morgan Stanley Raises Target Price to HK$138.5 Amid Strong H1 Revenue Expectations

Market Focus

Aug 20

On August 20, INNOVENT BIO rose 4.43% in regular trading, trading at HK$101.6/share, with turnover of HK$218 million.

On the news front, Morgan Stanley published a research note on August 19 raising its target price for the company to HK$138.5, citing strong first-half product revenue performance. This follows BlackRock's disclosure of a 139,500-share purchase on August 12 at HK$95.375 per share, lifting its stake to 5.01%.

The company previously announced that H1 product revenue exceeded RMB 8.2 billion, representing year-over-year growth of over 55%, with Q2 product revenue surpassing RMB 4.3 billion, up approximately 60% YoY — significantly beating market expectations. Multiple brokerages including Goldman Sachs (target HK$111.68), Citi (target HK$115), and CLSA (target HK$139.9) have maintained buy ratings. The company is scheduled to convene a board meeting on August 25 to approve interim results, further catalyzing market sentiment ahead of the formal earnings release.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1170813125"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170813125\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170813125?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170813125","market":"us","top_or_hot":-1,"title":"Movement Alert｜INNOVENT BIO Rises 4.43% in Regular Trading, Morgan Stanley Raises Target Price to HK$138.5 Amid Strong H1 Revenue Expectations","media":"Market Focus","content":"<p><p>On August 20, INNOVENT BIO rose 4.43% in regular trading, trading at HK$101.6/share, with turnover of HK$218 million.</p><p>On the news front, Morgan Stanley published a research note on August 19 raising its target price for the company to HK$138.5, citing strong first-half product revenue performance. This follows BlackRock's disclosure of a 139,500-share purchase on August 12 at HK$95.375 per share, lifting its stake to 5.01%.</p><p>The company previously announced that H1 product revenue exceeded RMB 8.2 billion, representing year-over-year growth of over 55%, with Q2 product revenue surpassing RMB 4.3 billion, up approximately 60% YoY — significantly beating market expectations. Multiple brokerages including Goldman Sachs (target HK$111.68), Citi (target HK$115), and CLSA (target HK$139.9) have maintained buy ratings. The company is scheduled to convene a board meeting on August 25 to approve interim results, further catalyzing market sentiment ahead of the formal earnings release.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INNOVENT BIO Rises 4.43% in Regular Trading, Morgan Stanley Raises Target Price to HK$138.5 Amid Strong H1 Revenue Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INNOVENT BIO Rises 4.43% in Regular Trading, Morgan Stanley Raises Target Price to HK$138.5 Amid Strong H1 Revenue Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-20 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 20, INNOVENT BIO rose 4.43% in regular trading, trading at HK$101.6/share, with turnover of HK$218 million.</p><p>On the news front, Morgan Stanley published a research note on August 19 raising its target price for the company to HK$138.5, citing strong first-half product revenue performance. This follows BlackRock's disclosure of a 139,500-share purchase on August 12 at HK$95.375 per share, lifting its stake to 5.01%.</p><p>The company previously announced that H1 product revenue exceeded RMB 8.2 billion, representing year-over-year growth of over 55%, with Q2 product revenue surpassing RMB 4.3 billion, up approximately 60% YoY — significantly beating market expectations. Multiple brokerages including Goldman Sachs (target HK$111.68), Citi (target HK$115), and CLSA (target HK$139.9) have maintained buy ratings. The company is scheduled to convene a board meeting on August 25 to approve interim results, further catalyzing market sentiment ahead of the formal earnings release.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1170813125","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170813125","pubTimestamp":1787189578,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 20, INNOVENT BIO rose 4.43% in regular trading, trading at HK$101.6/share, with turnover of HK$218 million.On the news front, Morgan Stanley published a research note on August 19 raising...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"走势提醒|信达生物常规交易上涨4.43%，摩根士丹利上半年营收预期强劲，目标价上调至138.5港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On August 20, INNOVENT BIO rose 4.43% in regular trading, trading at HK$101.6/share, with turnover of HK$218 million.On the news front, Morgan Stanley published a research note on August 19 raising its target price for the company to HK$138.5, citing strong first-half product revenue performance. This follows BlackRock's disclosure of a 139,500-share purchase on August 12 at HK$95.375 per share, lifting its stake to 5.01%.The company previously announced that H1 product revenue exceeded RMB 8.2 billion, representing year-over-year growth of over 55%, with Q2 product revenue surpassing RMB 4.3 billion, up approximately 60% YoY — significantly beating market expectations. Multiple brokerages including Goldman Sachs (target HK$111.68), Citi (target HK$115), and CLSA (target HK$139.9) have maintained buy ratings. The company is scheduled to convene a board meeting on August 25 to approve interim results, further catalyzing market sentiment ahead of the formal earnings release.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}